Durable five-year survival benefit1
TAFINLAR (dabrafenib) in combination with MEKINIST (trametinib) is indicated in adults for the treatment of BRAF V600-positive unresectable or metastatic melanoma.2,3
Landmark data demonstrate TAFINLAR + MEKINIST achieves durable overall survival and long-term progression-free survival benefits versus BRAF inhibitor alone that are maintained over five years. Treatment with TAFINLAR + MEKINIST is also associated with a well-established safety profile.1
Please select an option below to find out more about patient management, or the efficacy and safety profile of TAFINLAR + MEKINIST for the treatment of adult BRAF V600-positive metastatic melanoma.
- Robert C, et al. N Engl J Med 2019; 381:626–636.
- TAFINLAR (dabrafenib) Summary of Product Characteristics.
- MEKINIST (trametinib) Summary of Product Characteristics.